Digestive system

New health survey from PrecisionBiotics reveals fear about life after lockdown

Retrieved on: 
Wednesday, April 14, 2021
Branches of biology, Digestive system, Abdomen, Endocrine system, Gastrointestinal tract, Gut

How does it help or hinderthe ability to live well, work effectively and enjoy life?

Key Points: 
  • How does it help or hinderthe ability to live well, work effectively and enjoy life?
  • According to people who suffer from poor gut health, it is fundamental.\nA recent survey of over 1,000 people conducted in March 2021 by PrecisionBiotics has revealed some extraordinary insights from the people who suffer with the symptoms of poor gut health.
  • Exercise or antidepressants.\nIt is alarming to find from this survey that over 50% of respondents have suffered from gut health problems for nearly half their life.
  • The programme includes weekly tips, recipes, nutritional advice, monthly check ins and personalised guidance from gut health advisors as well as a free symptom tracker.

New health survey from PrecisionBiotics reveals fear about life after lockdown

Retrieved on: 
Wednesday, April 14, 2021
Branches of biology, Digestive system, Abdomen, Endocrine system, Gastrointestinal tract, Gut

How does it help or hinderthe ability to live well, work effectively and enjoy life?

Key Points: 
  • How does it help or hinderthe ability to live well, work effectively and enjoy life?
  • According to people who suffer from poor gut health, it is fundamental.\nA recent survey of over 1,000 people conducted in March 2021 by PrecisionBiotics has revealed some extraordinary insights from the people who suffer with the symptoms of poor gut health.
  • Exercise or antidepressants.\nIt is alarming to find from this survey that over 50% of respondents have suffered from gut health problems for nearly half their life.
  • The programme includes weekly tips, recipes, nutritional advice, monthly check ins and personalised guidance from gut health advisors as well as a free symptom tracker.

Enviromedica's Terraflora® Deep Immune Selected as Nexty Award Finalist

Retrieved on: 
Wednesday, April 14, 2021
Branches of biology, Digestive system, Immune system, Gastrointestinal tract

b'AUSTIN, Texas, April 13, 2021 /PRNewswire/ -- Terraflora Deep Immune, a leading-edge product in Enviromedica\'s next generation line of spore-based synbiotics, was just announced as a finalist for a highly coveted NEXTY Award.\nTerraflora Deep Immune, a leading-edge spore-based synbiotic, was just announced as a finalist for a highly coveted NEXTY award.\nThe NEXTY Awards recognize the most progressive, innovative, inspiring and trustworthy products in the natural products industry.

Key Points: 
  • b'AUSTIN, Texas, April 13, 2021 /PRNewswire/ -- Terraflora Deep Immune, a leading-edge product in Enviromedica\'s next generation line of spore-based synbiotics, was just announced as a finalist for a highly coveted NEXTY Award.\nTerraflora Deep Immune, a leading-edge spore-based synbiotic, was just announced as a finalist for a highly coveted NEXTY award.\nThe NEXTY Awards recognize the most progressive, innovative, inspiring and trustworthy products in the natural products industry.
  • With over 80% of the immune system residing in the gut, gut health is essential to immune health.
  • Terraflora Deep Immune is vegan, GMO-free, allergen-free, and is made without stearates, fillers, binders or flow agents.\nThe NEXTY Awards are connected to New Hope Network\'s largest annual natural product expos: Natural Products Expo West and Natural Products Expo East.
  • For more information or to shop Terraflora Deep Immune, visit www.enviromedica.com .\nView original content to download multimedia: http://www.prnewswire.com/news-releases/enviromedicas-terraflora-deep-im...\n'

New COVID-19 Clinical Trial on ImmunoSEB™ & ProbioSEB CSC3™

Retrieved on: 
Tuesday, April 13, 2021
Medical specialties, Clinical medicine, Branches of biology, Biomarkers, Digestive system, Bacteriology, Probiotic, Bacillus, C-reactive protein

b'CHINO, Calif., April 13, 2021 /PRNewswire/ -- Specialty Enzymes & Probiotics is proud to announce the recent publication of a new COVID-19 clinical trial in the Medical Journal of Advances in Clinical Toxicology.

Key Points: 
  • b'CHINO, Calif., April 13, 2021 /PRNewswire/ -- Specialty Enzymes & Probiotics is proud to announce the recent publication of a new COVID-19 clinical trial in the Medical Journal of Advances in Clinical Toxicology.
  • This randomized, multi-center, peer-reviewed clinical trial explored the safety and efficacy of the health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (Bacillus probiotics complex) as a supplemental therapy in confirmed mild to moderate COVID-19 patients.\nThe results found 93.33% of participants in the test arm showed clinical improvement on Day 10 versus 60% of patients in the control arm.
  • Patients in the test arm had a shorter duration of hospitalization, quicker recovery and faster reduction in CRP levels as compared to the control arm.
  • The enzyme and probiotic combination of ImmunoSEB & ProbioSEB CSC3 was shown to promote immune health.\n"During this unprecedented time, we are honored to offer natural solutions that can help people who are suffering," said Vic Rathi, President and CEO of Specialty Enzymes & Probiotics.

Nothin To Hide™…Nothing Like Your Old Rawhide

Retrieved on: 
Monday, April 12, 2021
Digestive system, Pet stores, Branches of biology, Medical specialties, Medicine, Leather, Rawhide, Choking, Chewing, Hide, Digestion, Chewy

However, ingesting rawhide can lead to significant choking, blockage and digestive issues.

Key Points: 
  • However, ingesting rawhide can lead to significant choking, blockage and digestive issues.
  • In fact, pet parents have been sharing stories about rawhide-triggered trips to emergency hospitals for many years.\nFieldcrest Farms Nothin\' to Hidechews by Ethical Products, Inc. offer a safer and more digestible chewing experience for dogs.
  • Pet parents can find Nothin\' to Hide at Petco, Chewy.com and neighborhood pet stores nationwide.\nLaboratory tests confirm that Nothin\' to Hide is highly digestible making it a far safer alternative to traditional rawhide.
  • The brand recently launched a new chew division, Fieldcrest Farms, which markets a complete line of natural, long lasting dog chews.\n'

Ben-Gurion University Researchers Introduce Novel Probiotic Yogurt-Based Treatment for Inflammatory Conditions

Retrieved on: 
Thursday, April 8, 2021
Branches of biology, Medical specialties, Food and drink, Bacteriology, Fermented dairy products, Vibrionales, Digestive system, Probiotic, Gram-negative bacteria, Kefir, Inflammatory bowel disease, Vibrio

BEER-SHEVA, Israel, April 8, 2021 /PRNewswire/ --Researchers at Ben-Gurion University of the Negev (BGU) have identified novel drug candidates based on molecules isolated from probiotic yogurt for combating pathogenic bacteria and for treating various inflammatory conditions, including inflammatory bowel disease (IBD) and COVID-19 related cytokine storms.

Key Points: 
  • BEER-SHEVA, Israel, April 8, 2021 /PRNewswire/ --Researchers at Ben-Gurion University of the Negev (BGU) have identified novel drug candidates based on molecules isolated from probiotic yogurt for combating pathogenic bacteria and for treating various inflammatory conditions, including inflammatory bowel disease (IBD) and COVID-19 related cytokine storms.
  • Kefir, a type of yogurt, is a fermented probiotic dairy drink made by inoculating milk with microorganism mixtures, particularly yeast and bacteria.
  • In particular, the BGU researchers demonstrated that the kefir-secreted molecules were able to significantly reduce virulence of Vibrio cholerae the causative agent of cholera.
  • In a follow-up study, the scientists observed that the isolated molecules had dramatic anti-inflammatory properties in various pathological conditions and disease models.

United States $10.7 Billion Plant Based Food Market to 2027

Retrieved on: 
Wednesday, April 7, 2021
Drinks, Food and drink, Non-alcoholic drinks, Liquids, Milk, Vegan cuisine, Digestive system, Food sensitivity, Lactose intolerance

DUBLIN, April 7, 2021 /PRNewswire/ -- The "United States Plant Based Food Market Forecast By Segments, Food Services, Merger and Acquisitions, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 7, 2021 /PRNewswire/ -- The "United States Plant Based Food Market Forecast By Segments, Food Services, Merger and Acquisitions, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The United States Plant-based Food Industry was valued at US$ 5.6 Billion in 2020 and is expected to increase to US$ 10.7 Billion in 2027.
  • Plant-Based Food Market in the United States is expected to grow with a CAGR of 9.69%.
  • Besides, lactose intolerance among infants and adults in the United States is a foremost issue boosting plant-based milk market growth.

Kyo-Dophilus Pro+ Synbiotic Brings the Best Benefits of Probiotics and Prebiotics to Gut Health

Retrieved on: 
Wednesday, April 7, 2021
Digestive system, Bacteriology, Probiotics, Prebiotic, Synbiotics, Biotic

Wakunaga of America has developed Kyo-Dophilus Pro+ Synbiotic chewable tablets to make taking probiotics and prebiotics more convenient and uncomplicated.

Key Points: 
  • Wakunaga of America has developed Kyo-Dophilus Pro+ Synbiotic chewable tablets to make taking probiotics and prebiotics more convenient and uncomplicated.
  • What I like about the Kyo-Dophilus Pro+ Synbiotic chewable supplement is that it is easy to take, especially for people who are pill adverse.
  • Each of the strains used in Pro+ Synbiotic have been carefully selected for clinically-studied digestive and immune benefits.
  • To learn more about Wakunagas full line of Kyo-Dophilus Probiotics including: Pro+ Synbiotic, Max, Daily, Multi 9, Enzyme+, Cran+ and Kids visit: www.wakunaga.com .

Reduction of Blood Lipids: A New Era for Cardiovascular Probiotics, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, April 7, 2021
Bacteria, Lactobacillaceae, Medical specialties, Gram-positive bacteria, Probiotics, Microbiology, Digestive system, Lactobacillus, Lactic acid bacteria, Lactobacillus paracasei, Lactobacillus acidophilus

Today, there is yet another potent option for the reduction of lipids and improvement in cardiovascular health: a multi-strain, Lactobacillus plantarum KABP formulation known as "Cardio Probiotic".

Key Points: 
  • Today, there is yet another potent option for the reduction of lipids and improvement in cardiovascular health: a multi-strain, Lactobacillus plantarum KABP formulation known as "Cardio Probiotic".
  • Many strains of lactic acid bacteria (LAB) from the genus Lactobacillus have been identified to possess probiotic properties.
  • Recent evidence has illustrated the potential of Lactobacillus plantarum KABP for cardiovascular health and lipid metabolism.
  • For more information, or to register for this event, visit Reduction of Blood Lipids: A New Era for Cardiovascular Probiotics.

Enterome to Present at Upcoming Conferences

Retrieved on: 
Wednesday, April 7, 2021
Microbiology, Environmental microbiology, Branches of biology, Medical specialties, Bacteriology, Microbiomes, Digestive system, Firmicutes, Gut microbiota, Microbiome, Immunotherapy

Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health.

Key Points: 
  • Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health.
  • Enterome is leveraging this unique ability to develop two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer, inflammatory and metabolic diseases:
    OncoMimics: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463).
  • Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.
  • Enterome is headquartered in Paris (France) and is backed by leading venture capital investors.